Alisha Bent

Clinical trials

• A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

  Principal investigator · Withdrawn · Phase 2

  M.D. Anderson Cancer Center

  2025–2026
• DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

  Principal investigator · Completed

  M.D. Anderson Cancer Center

  2021–2026
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

  Principal investigator · Active not recruiting · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2020–2026
• TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

  Study chair · Recruiting · Phase 2

  M.D. Anderson Cancer Center

  2022–2027